- Home
- EDSA vs TLPH Comparison
EDSA vs TLPH Comparison
Compare EDSA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- TLPH
- Stock Information
- Founded
- EDSA 2015
- TLPH 2005
- Country
- EDSA Canada
- TLPH United States
- Employees
- EDSA N/A
- TLPH N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- TLPH Health Care
- Exchange
- EDSA Nasdaq
- TLPH Nasdaq
- Market Cap
- EDSA 13.8M
- TLPH 10.6M
- IPO Year
- EDSA N/A
- TLPH 2011
- Fundamental
- Price
- EDSA $2.03
- TLPH $0.47
- Analyst Decision
- EDSA Strong Buy
- TLPH Strong Buy
- Analyst Count
- EDSA 2
- TLPH 1
- Target Price
- EDSA $13.00
- TLPH $6.00
- AVG Volume (30 Days)
- EDSA 33.4K
- TLPH 44.5K
- Earning Date
- EDSA 08-08-2025
- TLPH 08-13-2025
- Dividend Yield
- EDSA N/A
- TLPH N/A
- EPS Growth
- EDSA N/A
- TLPH N/A
- EPS
- EDSA N/A
- TLPH N/A
- Revenue
- EDSA N/A
- TLPH $27,000.00
- Revenue This Year
- EDSA N/A
- TLPH N/A
- Revenue Next Year
- EDSA N/A
- TLPH $14,533.26
- P/E Ratio
- EDSA N/A
- TLPH N/A
- Revenue Growth
- EDSA N/A
- TLPH N/A
- 52 Week Low
- EDSA $1.55
- TLPH $0.43
- 52 Week High
- EDSA $5.59
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- EDSA 52.89
- TLPH 35.99
- Support Level
- EDSA $1.91
- TLPH $0.45
- Resistance Level
- EDSA $2.14
- TLPH $0.52
- Average True Range (ATR)
- EDSA 0.12
- TLPH 0.03
- MACD
- EDSA 0.02
- TLPH -0.01
- Stochastic Oscillator
- EDSA 64.52
- TLPH 11.11
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.